Preventing Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children: New guidelines for prophylaxis

Pediatric Infectious Disease Journal

Volumn 15, Issue 2, 1996, Pages 165-168

  Grubman, Samuel ^a   Simonds, R J ^b  

^a ST VINCENT S HOSPITAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DAPSONE; PENTAMIDINE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CHILD; CHILD, PRESCHOOL; FEMALE; FORECASTING; HUMANS; INFANT; INFANT, NEWBORN; MALE; PNEUMONIA, PNEUMOCYSTIS;

EID: 0030046734     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199602000-00014     Document Type: Article

References (19)

1. Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MF. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993;270:470-3.
2. Thea DM, Lambert G, Weedon J, et al. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. Pediatrics 1996;97:59-64.
3. The European Collaborative Study Group. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. Br Med J 1994;308:437-40,
4. Simonds RJ, Lindegren ML, Thomas P, et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired HIV infection in the United States. N Engl J Med 1995;332:786-90.
5. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419-26.
6. Caldwell B, Lancaster J, Thomas P, et al. Children with symptomatic HIV infection: what medications are they receiving? [Abstract]. In: The 34th Interseience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994. Washington DC: American Society for Microbiology, 1994:36.
7. Oleske J, Mofenson L, Lenderking W, et al. PCP prophylaxis (PRO) among children followed in ACTG pediatric long-term protocol 219 [Abstract]. Clin Infect Dis 1994;19:611.
8. CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR 1991;40(RR-2):1-13.
9. CDC. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995;44(RR-4):1-11.
10. CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus (HIV). MMWR 1989;38(S-5):l-9.
11. Israele V, Wittek A, Courville T, Srugo I, Brunell P. Pneumocystis carinii pneumonia (PCP) in infants with CD4 counts greater than 2000 cells/mm3 [Abstract PoB 3855]. Presented at the VIII International Conference on AIDS. Amsterdam, July, 1992.
12. CDC. USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44(RR-8):1-34.
13. Wilfert CM, Masur H, Gross PA, et al. Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in infants and children born to women infected with human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl l):S132-3.
14. CDC. US Public Health Service recommendations for HIV counseling and testing for pregnant women. MMWR 1995;44(RR-7):1-15.
15. CDC. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(RR-12):1-10.
16. El-Sadr W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection. Clinical Practice Guideline No. 7. AHCPR Publication No. 94-0572. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1994.
17. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
18. CDC. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43(RR-11):1-20.
19. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breast-feeding. Lancet 1992;340:585-8.